1st Annual Regen Med Investor Day Platform to Bedside Marc Hedrick, MD President
Safe Harbor StatementThis presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. Allstatements, other than statements of historical fact, that address activities, events or developments that weintend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.Such statements are based upon certain assumptions and assessments made by our management in light oftheir experience and their perception of historical trends, current conditions, expected future developmentsand other factors they believe to be appropriate.The forward-looking statements included in this presentation involve known and unknown risks that relate toCytori’s future events or future financial performance and the actual results could differ materially from thosediscussed in this presentation. Risks and uncertainties that may cause Cytoris actual results to differmaterially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’sForm 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. Wewould advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filedwith the United States Securities and Exchange Commission for a more detailed description of these risks.The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptionsonly as of the date of this presentation and Cytori undertakes no duty or obligation to update or revisepublicly any forward-looking statements contained in this presentation as a result of new information, futureevents or changes in Cytori’s expectations.
Cytori Platform: Technology STEP 1 Harvest patient tissue (100cc) STEP 2 Separate & Process STEP 3 Technology for cell Deliver ADRCs to isolation, combination with other factors, Same Patient, ~1 hr. storage and clinical therapy
Cytori Platform: Model Goal: Leadership in Regenerative Medicine Research & Regulatory Clinical Commercial Development Approval Use Device Safety Self Pay Basic Approvals ScienceCAPITAL PROFIT Efficacy Reimbursement Product Therapeutic Development Approvals
Cytori Platform: Case Study Radiation Injury, BARDA Ischemia & Japan EU CV TrialsGen One EU Breast Breast Device Approval Sales Pilot Pivotal Other Approvals & Applications
Cytori Cell Therapy: US Government ContractDiscussions Award 3 Proof-of-concept Objectives 3 Objectives Trigger Option 1 ObjectiveBegin Announcement Ongoing Option 1 & 3 Triggers Option 22010 Fall, 2012 Q1, 2014 Q4, 2015 Cell viability $32.6 M Option 1 Pre-Award, White Papers, Animal model POC Proposal, Negotiation $45.5M Option 2 Next Gen device feasibility $4.7M Phase 1 Proof of Concept $23.4M Option 3 Commercial Acquisition at BARDA’s Discretion
Cytori Platform: Clinical Trials and Studies 43 total: 2 Cytori sponsored trials & 41 investigator studies USA EU AP 1 23 13Soft Tissue: 18 Wound: 7 Ischemia: 2 EMOrtho/Sport: 8Vital Organ: 8 6 Total: 43